Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
about
Metallic nickel nanoparticles may exhibit higher carcinogenic potential than fine particles in JB6 cellsZoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cellsHypoxia-inducible factor-1 as a therapeutic target in endometrial cancer managementPreliminary study on retinal vascular and oxygen-related changes after long-term silicone oil and foldable capsular vitreous body tamponade.Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells.SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilizationPathological and prognostic significance of hypoxia-inducible factor 1α expression in epithelial ovarian cancer: a meta-analysis.Expression of Hypoxia-inducible factor 1-α and vascular endothelial growth factor-C in locally advanced breast cancer patients.Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosisSNP rs2057482 in HIF1A gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery.Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilizationSelf-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.Expression and significance of hypoxia-inducible factor-1α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells.Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumorsAntiangiogenics and radiotherapy.Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.Nanodrug delivery in reversing multidrug resistance in cancer cells.Hypoxic tumor microenvironment in advanced retinoblastoma.Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistanceHIF-α Promotes Chronic Myelogenous Leukemia Cell Proliferation by Upregulating p21 Expression.Hypoxia: dual effect on the expression of transferrin receptor in human melanoma A375 cell line.The role of C/EBP-β LIP in multidrug resistance.Expression and significance of hypoxia-inducible factor-1α and survivin in laryngeal carcinoma tissue and cells.A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.A Humanized Anti-Interleukin 6 Receptor Monoclonal Antibody, Tocilizumab, for the Treatment of Endometriosis in a Rat Model.Mean Corpuscular Volume as a Predictive Factor of Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer.DJ-1 promotes survival of human colon cancer cells under hypoxia by modulating HIF-1α expression through the PI3K-AKT pathway
P2860
Q23920638-0D466564-4E43-4150-A857-9F5BDD9E14B0Q28486174-D24A9BBF-CA2E-45DF-8DE8-AE95962D9D24Q33652379-E11E2420-D38A-4D32-A804-BB92AE47AD7BQ33741703-F4CE1FDA-A751-4DF5-8DF8-3046B8CADCA5Q34152742-D6583960-A171-4313-A23E-148BBAE590EEQ34729713-F23F1B86-2D1C-4CD9-9F68-E08D82AB17EAQ35171434-0E08EB8A-3846-4904-A583-E8345665FB1AQ35179664-7233C055-DFB6-4ACF-8DFA-7926A859742EQ35449469-0C4FC69E-29C3-43B9-84F1-AC0EA43763D9Q35785191-E5D9AD98-AC30-4291-B558-EC1644896ED7Q36293304-A1CBBEEB-9895-4FF6-84AF-A1567D4240A4Q36544608-15C4BF7A-9FFD-4F9B-9C17-CA09ECFC7B6EQ37092712-39ADA67A-7878-4E93-9E43-C9BB0D184B21Q37190433-0C649D07-5420-4676-B1A8-D8B273C0CE02Q37222791-6085F5FE-EACA-4292-8DF6-8E7415A67083Q37230670-C88166AA-7E2A-4940-A396-16A8D981D236Q38234908-B7B84C37-4D07-4F22-B462-9CB74EC4CD95Q38395896-4389314F-900D-447F-94B1-000F1B0C06E6Q38915770-913983BC-9BF2-4BD3-B16A-C7BA4D1779A4Q38919044-740093A5-E357-4693-B590-1DC1DFCC7DA8Q40069868-F5FBE3F4-1A9C-445D-A487-FF7F0AC071B0Q42474136-3B51E357-BC56-4DFB-9FEE-982D1E281A27Q44400746-D8059E60-113F-470A-A87B-AD03723B4531Q44502775-C93D13AF-1697-4552-99FE-CA15C40CCC9DQ50960074-B0AAD830-CDDD-4AED-9B25-167DFD62A94EQ55233773-0A89385A-E298-4203-85A2-0C260AA623F7Q58551758-1C4EDDAE-777B-4592-B79D-26793852F1EF
P2860
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
@ast
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
@en
type
label
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
@ast
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
@en
prefLabel
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
@ast
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
@en
P2093
P1476
Oncological implications of hypoxia inducible factor-1alpha (HIF-1alpha) expression.
@en
P2093
Aoife M Shannon
David Bouchier-Hayes
James Geraghty
Jill L O'Donnell
Judith Harmey
Myles R Joyce
P304
P356
10.1016/J.CTRV.2006.05.003
P577
2006-08-04T00:00:00Z